Bafna Pharmaceuticals Ltd

📈 Bafna Pharma’s Credit Outlook Upgraded to ‘Positive’ by ICRA

- ICRA revises Bafna Pharmaceuticals’ credit outlook from ‘Stable’ to ‘Positive’.

- Total bank loan facilities rated: ₹50.00 Crores.

- Long-term rating reaffirmed at [ICRA] BB+ (outlook now ‘Positive’).

- Short-term rating remains unchanged at [ICRA] A4+.

- Breakdown of rated instruments:

• Term Loan: ₹25.87 Crores

• Cash Credit: ₹20.00 Crores

• Letter of Credit: ₹5.00 Crores

• Unallocated: ₹4.13 Crores.

- Rating action announced on January 23, 2026; next review due in one year.